{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Arcturus Therapeutics Holdings, Inc.
Arcturus Therapeutics Hits 52-Week Low at $6.02 Amid Major Decline
Arcturus Therapeutics Holdings, Inc. has reached a new 52-week low, reflecting a challenging year marked by an 81.06% decline in stock price. The company reported a decrease in net sales and a negative pre-tax profit, alongside ongoing financial difficulties indicated by negative return on equity and EBITDA.
Arcturus Therapeutics Hits 52-Week Low at $6.72 Amid Ongoing Struggles
Arcturus Therapeutics Holdings, Inc. has hit a new 52-week low, reflecting significant challenges in its financial performance. The company has seen a substantial decline in stock price over the past year, with negative returns on equity and disappointing quarterly results, raising concerns about its future viability.
Arcturus Therapeutics Hits 52-Week Low at $7.26 Amid Financial Struggles
Arcturus Therapeutics Holdings, Inc. has reached a new 52-week low, reflecting a challenging year with a significant stock price decline. The company reported a decrease in net sales and consecutive negative quarterly results, alongside a low return on equity, as it faces ongoing financial difficulties.
Arcturus Therapeutics Hits New 52-Week Low at $7.76
Arcturus Therapeutics Holdings, Inc. has reached a new 52-week low, reflecting a difficult year with a significant stock price decline. The company faces ongoing financial challenges, including negative return on equity and a decrease in net sales, while its market capitalization stands at USD 484 million.
Arcturus Therapeutics Hits 52-Week Low at $7.93 Amid Financial Struggles
Arcturus Therapeutics Holdings, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company faces ongoing financial challenges, including negative return on equity, a high debt-to-equity ratio, and declining net sales, contributing to its underperformance in the market.
Is Arcturus Therapeutics Holdings, Inc. technically bullish or bearish?
As of October 24, 2025, Arcturus Therapeutics has a mildly bullish technical trend, supported by daily moving averages and a weekly KST signal, but tempered by bearish weekly and monthly Bollinger Bands and mixed MACD signals.
Is Arcturus Therapeutics Holdings, Inc. technically bullish or bearish?
As of October 24, 2025, Arcturus Therapeutics Holdings, Inc. shows a mildly bullish trend overall, but caution is advised due to mixed signals from MACD, bearish Bollinger Bands, and conflicting indicators.
Is Arcturus Therapeutics Holdings, Inc. technically bullish or bearish?
As of October 24, 2025, Arcturus Therapeutics Holdings, Inc. shows a mildly bullish trend based on daily moving averages, but caution is advised due to a mildly bearish weekly MACD and bearish Bollinger Bands, with a 1-year return of -40.95% compared to the S&P 500's 16.90%.
Arcturus Therapeutics Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators
Arcturus Therapeutics Holdings, Inc. has recently revised its evaluation amid notable stock fluctuations, closing at $20.31 and reaching a high of $22.40. The stock has shown significant volatility over the past year and has outperformed the S&P 500 year-to-date, reflecting its resilience in the biotechnology sector.
Is Arcturus Therapeutics Holdings, Inc. technically bullish or bearish?
As of September 26, 2025, Arcturus Therapeutics shows a bullish trend overall, supported by bullish MACD and moving averages, though the weekly RSI indicates short-term weakness and mixed signals from other indicators suggest caution.
Is Arcturus Therapeutics Holdings, Inc. technically bullish or bearish?
As of September 26, 2025, Arcturus Therapeutics shows a bullish trend supported by positive MACD and moving averages, despite a bearish weekly RSI, with recent performance outperforming the S&P 500 in the short term but underperforming over the longer term.
Is Arcturus Therapeutics Holdings, Inc. technically bullish or bearish?
As of September 26, 2025, Arcturus Therapeutics Holdings, Inc. shows a bullish technical trend, supported by positive MACD, Bollinger Bands, and moving averages, despite mixed performance indicators and underperformance over longer periods compared to the S&P 500.
Is Arcturus Therapeutics Holdings, Inc. technically bullish or bearish?
As of September 2, 2025, Arcturus Therapeutics shows a mildly bullish trend with mixed signals from various indicators, having outperformed the S&P 500 recently but underperformed over the longer term, suggesting caution is warranted.
Is Arcturus Therapeutics Holdings, Inc. overvalued or undervalued?
As of March 7, 2024, Arcturus Therapeutics Holdings, Inc. is considered overvalued and risky due to negative earnings, a -5.41% ROE, and poor long-term performance, despite a recent short-term gain of 8.76%.
Is Arcturus Therapeutics Holdings, Inc. overvalued or undervalued?
As of March 7, 2024, Arcturus Therapeutics Holdings, Inc. is considered risky and overvalued due to negative earnings and poor financial ratios, including a Price to Book Value of 1.48 and an EV to EBITDA of -3.10%, especially when compared to peers like Innoviva, Inc. and Collegium Pharmaceutical, Inc. with P/E ratios of 15.38 and 14.78, respectively, and a significant decline of -54.43% in the past year versus the S&P 500's 10.26% gain.
Is Arcturus Therapeutics Holdings, Inc. technically bullish or bearish?
As of May 19, 2025, the market trend is mildly bearish, indicated by daily moving averages and Bollinger Bands, despite some mildly bullish signals from weekly indicators, suggesting caution due to overall bearish sentiment.
Who are in the management team of Arcturus Therapeutics Holdings, Inc.?
As of March 2022, the management team of Arcturus Therapeutics includes Dr. Peter Farrell (Independent Chairman), Mr. Joseph Payne (CEO), Mr. Andrew Sassine (CFO), and several independent directors: Ms. Karah Parschauer, Mr. James Barlow, Dr. Edward Holmes, and Dr. Magda Marquet. This team combines executive leadership with independent oversight for diverse governance.
What does Arcturus Therapeutics Holdings, Inc. do?
Arcturus Therapeutics Holdings, Inc. is a clinical-stage company focused on mRNA medicines and vaccines in the Pharmaceuticals & Biotechnology industry, with a market cap of $333.04 million. As of March 2025, it reported net sales of $25 million and a net loss of $14 million.
How big is Arcturus Therapeutics Holdings, Inc.?
As of Jun 18, Arcturus Therapeutics Holdings, Inc. has a market capitalization of 333.04 million and reported net sales of 131.28 million with a net profit of -68.21 million over the latest four quarters. Shareholder's funds were 240.98 million, and total assets were 344.07 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
